Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Newly Diagnosed Classical Hodgkin Lymphoma Treatment Study

Clinical Trial Title: 
A randomized phase 3 study of brentuximab vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults.
Clinical Trial Protocol ID: 
15070801-CAO1
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

Response directed therapy in high risk pediatric Hodgkin lymphoma with brentuximab added to standard therapy.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are between 2 and 22 years of age at the time of enrollment.
  • Have newly  diagnosed, pathologically confirmed cHL meeting one of the following Ann Arbor stages:
    • Stage IIB with bulk
    • Stage IIIB
    • Stage IVA
    • Stage IVB

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Pediatric Cancers and Blood Disorders
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane